These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35793925)

  • 1. Performance of HPV E4 and p16
    Damgaard RK; Jenkins D; de Koning MN; Quint WG; Stoler MH; Doorbar J; Kahlert J; Gravitt PE; Steiniche T; Petersen LK; Hammer A
    BMJ Open; 2022 Jul; 12(7):e059593. PubMed ID: 35793925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cervical biopsies of women with HIV and HPV co-infection using p16
    Kremer WW; Vink FJ; van Zummeren M; Dreyer G; Rozendaal L; Doorbar J; Bleeker MCG; Meijer CJLM
    Mod Pathol; 2020 Oct; 33(10):1968-1978. PubMed ID: 32249820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM.
    Griffin H; Soneji Y; Van Baars R; Arora R; Jenkins D; van de Sandt M; Wu Z; Quint W; Jach R; Okon K; Huras H; Singer A; Doorbar J
    Mod Pathol; 2015 Jul; 28(7):977-93. PubMed ID: 25953390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of high-grade cervical intraepithelial neoplasia by p16
    Vink FJ; Dick S; Heideman DAM; De Strooper LMA; Steenbergen RDM; Lissenberg-Witte BI; ; Floore A; Bonde JH; Oštrbenk Valenčak A; Poljak M; Petry KU; Hillemanns P; van Trommel NE; Berkhof J; Bleeker MCG; Meijer CJLM
    Int J Cancer; 2021 Aug; 149(3):707-716. PubMed ID: 33729551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing.
    Zhang G; Yang B; Abdul-Karim FW
    Int J Gynecol Pathol; 2015 Mar; 34(2):180-6. PubMed ID: 25675189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China.
    Liao GD; Sellors JW; Sun HK; Zhang X; Bao YP; Jeronimo J; Chen W; Zhao FH; Song Y; Cao Z; Zhang SK; Xi MR; Qiao YL
    Int J Cancer; 2014 Apr; 134(7):1715-24. PubMed ID: 24105727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases.
    Byun SW; Lee A; Kim S; Choi YJ; Lee YS; Park JS
    Int J Med Sci; 2013; 10(12):1602-7. PubMed ID: 24151431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies.
    Dray M; Russell P; Dalrymple C; Wallman N; Angus G; Leong A; Carter J; Cheerala B
    Pathology; 2005 Apr; 37(2):112-24. PubMed ID: 16028838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
    Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
    Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of correlation between p16INK4a staining, specific subtype of human papillomavirus, and progression of LSIL/CIN1 lesions: first comparative study.
    Razmpoosh M; Sansregret A; Oligny LL; Patey N; Dormoy-Raclet V; Ducruet T; Bouron-Dal Soglio D
    Am J Clin Pathol; 2014 Jul; 142(1):104-10. PubMed ID: 24926093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of HPV16 and high-grade cytology in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2.
    Damgaard RK; Jenkins D; Stoler MH; van de Sandt MM; Lycke KD; de Koning MNC; Quint WGV; Steiniche T; Petersen LK; Hammer A
    Acta Obstet Gynecol Scand; 2023 Sep; 102(9):1227-1235. PubMed ID: 37469102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology.
    Castle PE; Adcock R; Cuzick J; Wentzensen N; Torrez-Martinez NE; Torres SM; Stoler MH; Ronnett BM; Joste NE; Darragh TM; Gravitt PE; Schiffman M; Hunt WC; Kinney WK; Wheeler CM; ;
    Arch Pathol Lab Med; 2020 Jun; 144(6):725-734. PubMed ID: 31718233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia.
    Ishikawa M; Fujii T; Saito M; Nindl I; Ono A; Kubushiro K; Tsukazaki K; Mukai M; Nozawa S
    Int J Gynecol Cancer; 2006; 16(1):347-53. PubMed ID: 16445657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grading immunohistochemical markers p16
    Leeman A; Jenkins D; Marra E; van Zummeren M; Pirog EC; van de Sandt MM; van Eeden A; Schim van der Loeff MF; Doorbar J; de Vries HJC; van Kemenade FJ; Meijer CJLM; Quint WGV
    Br J Dermatol; 2020 Apr; 182(4):1026-1033. PubMed ID: 31302935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.
    Wu TJ; Smith-McCune K; Reuschenbach M; von Knebel Doeberitz M; Maloba M; Huchko MJ
    BMJ Open; 2016 Sep; 6(9):e012547. PubMed ID: 27625065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of p16-INK4A protein in women with negative or CIN1 histology result: a follow-up study.
    Pacchiarotti A; Ferrari F; Bellardini P; Chini F; Collina G; Dalla Palma P; Ghiringhello B; Maccallini V; Musolino F; Negri G; Pisa R; Sabatucci I; Giorgi Rossi P
    Int J Cancer; 2014 Feb; 134(4):897-904. PubMed ID: 23913416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears.
    Murphy N; Ring M; Killalea AG; Uhlmann V; O'Donovan M; Mulcahy F; Turner M; McGuinness E; Griffin M; Martin C; Sheils O; O'Leary JJ
    J Clin Pathol; 2003 Jan; 56(1):56-63. PubMed ID: 12499437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
    Stănculescu R; Brătilă E; Bauşic V; Vlădescu T
    Rom J Morphol Embryol; 2013; 54(4):1061-5. PubMed ID: 24399002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.